是如何分组的？

The second trial evaluated CYC   (intravenously at a dose of 600 mg/m2/month) compared with placebo in 45   patients with SSc-ILD.59 Active treatment included six infusions of CYC given   at 4-week intervals followed by oral azathioprine (2.5 mg/kg/day) or placebo   for 6 months. Prednisolone (20 mg on alternate days) was co-administered in   the active treatment group. The mean adjusted between-group difference in FVC   was 4.2% in favour of CYC, which just missed statistical significance (p=0.08).   The lung diffusing capacity for carbon monoxide and other outcome measures   did not improve.59   

第二项试验在45例SSc-ILD患者中对CYC（静脉注射剂量为600   mg / m2 /月）和安慰剂进行了评估.59   积极治疗包括输注CYC6次，每隔4周一次，口服硫唑嘌呤（2.5   mg/kg/天）或安慰剂，疗程6个月。积极治疗组同时服用强的松（每隔一天服用20毫克）。FVC组间差异的平均校正值为4.2%，有利于CYC，差一点达到统计学意义（p=0.08）。一氧化碳的肺部扩散能力和其他结果指标没有改善。59

是如何分组的？

1治疗组：CYC（静脉注射剂量为600   mg / m2 /月）+强的松 继而硫唑嘌呤

                 安慰剂组

2、                                                                                                硫唑嘌呤

治疗组：CYC（静脉注射剂量为600   mg / m2 /月）+强的松 继而分为上下两组

                                                                                                       安慰剂